Citadel Advisors
BIOA

Citadel Advisors’s BioAge Labs BIOA Stock Holding History

Citadel Advisors’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$301K Buy
+17,200
New +$331K ﹤0.01% 10469
2025
Q4 		– Sell
-23,300
Closed -$137K – 14363
2025
Q3 		$137K Sell
23,300
-1,000
-4% -$4.68K ﹤0.01% 11604
2025
Q2 		$100K Buy
+24,300
New +$97.9K ﹤0.01% 11342

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Citadel Advisors's BIOA Position: Q1 2026 in Review

Citadel Advisors sold out of BioAge Labs (BIOA) in Q1 2026, closing a stake of 230,543 shares — an estimated $4.44M sold.

Citadel Advisors first reported a position in BIOA in Q3 2024 and held it in 4 quarters. The position peaked at $4.45M in Q3 2024. 144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

  • Citadel Advisors reported no remaining BioAge Labs position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 230,543 BioAge Labs shares in Q1 2026, an estimated $4.44M.
  • Citadel Advisors first reported a position in BioAge Labs in Q3 2024 and held it in 4 quarters.
  • Citadel Advisors's BioAge Labs position peaked at $4.45M in Q3 2024.
  • 144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.